Theophylline
From Anvita Health Wiki
Contents |
Introduction
- Tradenames: Slo-Phyllin, Elixophyllin, Theolair.
- Slo-Bid, Slo-Phyllin, Theo-Dur, Theolair-SR & Uni-Dur taken off the US market in 2001. [7]
- Remaining forms of theohylline include:
- Uniphyl, T-phyl, Theo-24, Theolair & generics
- Uniphyl, T-phyl, Theo-24, Theolair & generics
Indications
- reactive airway disease ( asthma & COPD)
- used in combination with beta-2 adrenergic receptor agonists
- neonatal apnea/ bradycardia
Contraindications
- uncontrolled arrhythmias
- uncontrolled peptic ulcer disease
Dosage
- Oral:
- Tabs: 60, 100, 200, 300 mg.
- Liquid: (Theolair) 80 mg/15 mL (15 mL, 19 mL, 30 mL, 480 mL).
- Sustained release (once daily):
- Tradenames: Uniphyl, Theo-24.
- 400 mg PO QHS (give once a day at bedtime)
- Tabs: 100, 200, 300, 400 mg.
- Sustained release ( twice daily):
- Tradenames: Theo-Dur, Slo- bid.
- Tabs: 100, 200, 300, 450 mg.
- Pediatrics: sprinkles?: Tradename: Theo-Dur.
- Tabs: 50, 75, 125, 200 mg.
- Caution: dosage should be decreased by 50% in patients with:
- heart failure
- severe hypoxemia
- hepatic insuffciency
- seizures
- hyperthyroidism
- hypertension
Pharmacokinetics
- onset of action is 15 minutes after an IV loading dose
- absorption of oral formulation is variable
- food may effect absorption (+ or -)
- therapeutic range: 8-20 ug/mL, 5-12 ug/mL for COPD [8]
- metabolized in the liver by cyt P450 1A2
- elimination 1/2life:
- Conditions/disorders that alter theophylline metabolism
- conditions that decrease theophylline levels
- conditions that increase theophylline levels
- elimination via liver
- protein binding = 56 %
- elimination by hemodialysis = -
- elimination by hemoperfusion = -
- elimination by peritoneal dialysis = -
Monitor
- serum theophylline (see Laboratory: below)
- when intiating therapy
- before & after increasing dose
- when toxicity is suspected
- worsening illness predisposing to toxicity
- after smoking cessation
- after adding or stopping an interacting drug
- at least annually [9]
Adverse-effects
- not common (1-10%)
- uncommon (< 1%)
- rash, insomnia, irritability, tremor, seizures, gastric irritation, allergic reactions
- other
- arrhythmias & convulsions have occurred with serum levels > 35 ug/mL
- rapid IV administration may be associated with hypotension, syncope & cardiac arrest
- adverse effects umcommon at serum theophylline concentrations < 20 ug/mL
- Toxicity: best treated by charcoal & hemoperfusion.
Drug-interactions
- drugs that decrease theophylline levels
- phenytoin ( Dilantin)
- carbamazepine ( Tegretol)
- furosemide ( Lasix)
- rifampin
- beta-adrenergic receptor agonists
- ketoconazole
- phenobarbital
- aminoglutethimide
- any drug that induces cyt P450 1A2
- drugs that increase theophylline levels
-
- allopurinol
- propranolol
- caffeine
- cimetidine & possibly ranitidine
- mexiletine
- amiodarone
- oral contraceptives
- any drug that inhibits cyt P450 1A2
- theophylline may decrease the effects of phenytoin
- theophylline may have synergistic toxicity with sympathomimetics
Test-interactions
- chemical interferences
- theophylline may decrease
- theophylline may increase: serum uric acid
Laboratory
Mechanism-of-action
- (proposed [2])
- inhibits breakdown of cAMP
- inhibition of cGMP
- enhanced adrenergic output to airway smooth muscle
- antagonism of adenosine receptors
- stimulation of endogenous catecholamines
- decrease in [Ca+2] into bronchial smooth muscle cells or release of [Ca+2] from sarcoplasmic reticulum
- dose-dependent increase in respiratory muscle contractility
- relaxes smooth muscle of bronchial airways & pulmonary blood vessels
- diuretic
- coronary vasodilator
- cardiac stimulant
- CNS stimulant
More General Terms
Additional Terms
- cytochrome p450 1A2 (cytochrome P3-450, phenacetin deethylase, cytochrome p450-4, CYP1A2)
- theophylline in serum/plasma
Internet Database
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 741-42
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
- Clinical Diagnosis & Management by Laboratory Methods, 19th edition, J.B. Henry (ed), W.B. Saunders Co., Philadelphia, PA. 1996, pg 10
- Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelpha 1995
- Prescriber's Letter 8(9):51 2001
- Medical Knowledge Self Assessment Program (MKSAP) 14, American College of Physicians, Philadelphia 2006
- Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Detail-Document#: [1] (subscription needed) [2]
